Clinical and Economic Consequences of Vancomycin and Fidaxomicin for the Treatment of Clostridium difficile Infection in Canada
BACKGROUND: Clostridium difficile infection (CDI) represents a public health problem with increasing incidence and severity.
Main Authors: | Monika Wagner, Louis Lavoie, Mireille Goetghebeur |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2014-01-01
|
Series: | Canadian Journal of Infectious Diseases and Medical Microbiology |
Online Access: | http://dx.doi.org/10.1155/2014/793532 |
Similar Items
-
Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
by: Christine Lee, et al.
Published: (2016-01-01) -
Clostridium difficile infections and fidaxomicin treatment
by: Laura Fascio Pecetto
Published: (2014-12-01) -
Cost-effectiveness Analysis of Fidaxomicin versus Vancomycin for the Treatment of Clostridium Difficile Infection in Taiwan
by: Ya-Ling Wang, et al.
Published: (2018) -
Fidaxomicin - the new drug for Clostridium difficile infection
by: Chetana Vaishnavi
Published: (2015-01-01) -
Proteomic Signatures of <i>Clostridium difficile</i> Stressed with Metronidazole, Vancomycin, or Fidaxomicin
by: Sandra Maaß, et al.
Published: (2018-11-01)